GSK adds to COPD pipeline as Exscientia deal bears fruitAI drug research firm Exscientia has delivered the first candidate molecule to its partner GlaxoSmithKline following an R&D Share XGSK adds to COPD pipeline as Exscientia deal bears fruithttps://pharmaphorum.com/about-pharmaphorum/gsk-adds-to-copd-pipeline-as-exscientia-deal-bears-fruit/
Terms & ConditionsGENERAL TERMS AND CONDITIONS Introduction The website www.pharmaphorum.com (“Website”, “Site”) is a Site owned and operated by pharmaphorum Share XTerms & Conditionshttps://pharmaphorum.com/about-pharmaphorum/terms-and-conditions/
Privacy PolicyIntroduction pharmaphorum media Limited (“We”, “Us”, “Our”, “pharmaphorum”) respects the privacy of every individual who visits Our website Share XPrivacy Policyhttps://pharmaphorum.com/about-pharmaphorum/privacy-policy/
About pharmaphorumAbout pharmaphorum media The world of healthcare is changing rapidly and the pharma industry must adapt to ensure Share XAbout pharmaphorumhttps://pharmaphorum.com/about-pharmaphorum/about-pharmaphorum/
Contact Us You can follow pharmaphorum on our social media channels: pharmaphorum on LinkedIn pharmaphorum on Twitter pharmaphorum on Share XContact Ushttps://pharmaphorum.com/about-pharmaphorum/contact-us/
AdvertiseIn an increasingly noisy world, raising or maintaining awareness of your company, products and services is getting ever Share XAdvertisehttps://pharmaphorum.com/about-pharmaphorum/advertise/
ContributeIf you enjoy reading the content on pharmaphorum and want to get more actively involved there are a Share XContributehttps://pharmaphorum.com/about-pharmaphorum/contribute/
